Company News: GlaxoSmithKline and Covidien

Share this article:

GlaxoSmithKline reported steady second-quarter revenue, with total “underlying sales” growth as being up 5%. Accounting for some of this increase in sales was the pharma's pandemic flu products, as well as type 2 diabetes drug Avandia, and genital herpes drug Valtrex. US revenues grew by about 3%, much in part driven by sales for Advair, indicated for the treatment of asthma and COPD.

Covidien has released Q3 revenue information, reporting net sales as being up 14%, and an increase of medical device sales by 22%. The company did not include any significant pipeline updates in its third-quarter report. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions